Allergic Conjunctivitis - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 71
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AB9137ABF19EN
Leaflet:

Download PDF Leaflet

Allergic Conjunctivitis - Pipeline Review, H2 2016
Allergic Conjunctivitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2016, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 1, 8 and 1 respectively for Allergic Conjunctivitis.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Allergic Conjunctivitis Overview
Therapeutics Development
Pipeline Products for Allergic Conjunctivitis - Overview
Allergic Conjunctivitis - Therapeutics under Development by Companies
Allergic Conjunctivitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Allergic Conjunctivitis - Products under Development by Companies
Allergic Conjunctivitis - Companies Involved in Therapeutics Development
Accolade Pharmaceuticals, LLC
Aldeyra Therapeutics Inc
Allergan Plc
Clevexel Pharma SA
Griffin Discoveries BV
NicOx S.A.
Ocular Therapeutix, Inc.
Ohr Pharmaceutical Inc.
Portola Pharmaceuticals, Inc.
Re-Pharm Limited
Sylentis S.A.U.
Xencor, Inc.
Allergic Conjunctivitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ADX-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGN-229666 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cetirizine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone acetate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Allergic Conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GD-134 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GD-136 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRT-2761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-0217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYL-116011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XmAb-7195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Zafi-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergic Conjunctivitis - Dormant Projects
Allergic Conjunctivitis - Discontinued Products
Allergic Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Sep 26, 2016: Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day
Jun 06, 2016: Ocular Therapeutix Announces Topline Results of Second Phase 3 Clinical Trial of DEXTENZA for the Treatment of Allergic Conjunctivitis
Feb 29, 2016: Aldeyra Therapeutics Reports Positive Results From Phase IIa Clinical Trial in Subjects With Allergic Conjunctivitis
Dec 16, 2015: Aldeyra Therapeutics Announces Last Patient Dosed in Phase II Trial of NS2 in Patients with Allergic Conjunctivitis
Nov 24, 2015: Ocular Therapeutix Begins Enrollment in its Second Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis
Nov 12, 2015: Ora-CAC Model Delivers Successful Phase 3 Data for Ocular Therapeutix's DEXTENZA for Treatment of Allergic Conjunctivitis
Oct 22, 2015: Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis
Sep 29, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase IIa Clinical Trial
Jun 16, 2015: Ocular Therapeutix Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA for the Treatment of Allergic Conjunctivitis
Nov 24, 2014: Ora-CAC Model Provided Platform for Recent Positive Phase 2 Data for Ocular Therapeutix’s OTX-DP in Allergic Conjunctivitis
Nov 12, 2014: Ocular Therapeutix Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 71

LIST OF TABLES

Number of Products under Development for Allergic Conjunctivitis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016
Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, H2 2016
Allergic Conjunctivitis - Pipeline by Allergan Plc, H2 2016
Allergic Conjunctivitis - Pipeline by Clevexel Pharma SA, H2 2016
Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H2 2016
Allergic Conjunctivitis - Pipeline by NicOx S.A., H2 2016
Allergic Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H2 2016
Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc., H2 2016
Allergic Conjunctivitis - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
Allergic Conjunctivitis - Pipeline by Re-Pharm Limited, H2 2016
Allergic Conjunctivitis - Pipeline by Sylentis S.A.U., H2 2016
Allergic Conjunctivitis - Pipeline by Xencor, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Allergic Conjunctivitis - Dormant Projects, H2 2016
Allergic Conjunctivitis - Dormant Projects (Contd..1), H2 2016
Allergic Conjunctivitis - Discontinued Products, H2 2016 61

LIST OF FIGURES

Number of Products under Development for Allergic Conjunctivitis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Allergic Conjunctivitis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: